Compare PDS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | JANX |
|---|---|---|
| Founded | 1951 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 992.1M | 975.7M |
| IPO Year | 1998 | 2021 |
| Metric | PDS | JANX |
|---|---|---|
| Price | $84.63 | $16.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $122.33 | $47.00 |
| AVG Volume (30 Days) | 95.8K | ★ 688.7K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.53 | $12.12 |
| 52 Week High | $103.80 | $35.34 |
| Indicator | PDS | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 53.93 |
| Support Level | $83.72 | $13.13 |
| Resistance Level | $86.80 | $16.68 |
| Average True Range (ATR) | 2.91 | 0.65 |
| MACD | 0.98 | 0.03 |
| Stochastic Oscillator | 92.64 | 67.55 |
Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.